The direct-to-consumer (DTC) genetic testing market is projected to grow at a CAGR of ~12% over the forecast period. Major ...

Shares of Myriad Genetics were higher after it announced early access to the FirstGene Multiple Prenatal Screen. The stock was up 9.2% to $4.87 Tuesday and is down about 64% this year.

Of the 30 companies included in the list, 15 saw their stock prices decline, while 15 saw their share prices rise.

Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested. Precise MRD detected tumor fractions as ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...

Lisa Roberts has raised a family, reached an impressively high level in her career, and been an anchor for her mother and other family members. Suddenly, within a ...

Myriad Genetics, Inc. (NASDAQ: MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

In addition to the MRD oral abstract, additional research highlights include: “We have an exciting, diverse, and sizable slate of oncology results being presented at ASCO this year, where each ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Fintel reports that on May 21, 2025, Scotiabank downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Sector ...

Former President Joe Biden was diagnosed with prostate cancer on Friday, according to media reports. While the diagnosis, which Biden received on May 16, indicates the former president has one of the ...